{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T18:07:05Z","timestamp":1771524425102,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,10,22]],"date-time":"2009-10-22T00:00:00Z","timestamp":1256169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s11095-009-9991-2","type":"journal-article","created":{"date-parts":[[2009,10,21]],"date-time":"2009-10-21T17:18:42Z","timestamp":1256145522000},"page":"151-160","source":"Crossref","is-referenced-by-count":49,"title":["Inhalable Antibiotic Delivery Using a Dry Powder Co-delivering Recombinant Deoxyribonuclease and Ciprofloxacin for Treatment of Cystic Fibrosis"],"prefix":"10.1007","volume":"27","author":[{"given":"Yan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Tsifansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Jung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae In","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,22]]},"reference":[{"key":"9991_CR1","first-page":"21","volume-title":"Diagnosis of Cystic Fibrosis. Cystic Fibrosis Medical Care","author":"DM Orenstein","year":"2000","unstructured":"Orenstein DM, Rosenstein BJ, Stern RC. Diagnosis of Cystic Fibrosis. Cystic Fibrosis Medical Care. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 21\u201353."},{"key":"9991_CR2","unstructured":"Genetic Testing for Cystic Fibrosis. NIH Consens Statement Online. 1997;15:1\u201337."},{"key":"9991_CR3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJM199607183350307","volume":"335","author":"BW Ramsey","year":"1996","unstructured":"Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. New Engl J Med. 1996;335:179\u201388.","journal-title":"New Engl J Med"},{"key":"9991_CR4","unstructured":"Murphy TM, Rosenstein BJ. Advances in the science and treatment of cystic fibrosis lung diseases: A continuing medical education resource, Duke University Medical Center & Health System, Durham, North Carolina."},{"key":"9991_CR5","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1164\/ajrccm.162.5.9909009","volume":"162","author":"NN Sanders","year":"2000","unstructured":"Sanders NN, De Smedt SC, Van Rompaey E, Simoens P, De Baets F, Demeester J. Cystic fibrosis sputum. A barrier to the transport of nanospheres. Am J Respir Crit Care Med. 2000;162:1905\u201311.","journal-title":"Am J Respir Crit Care Med"},{"key":"9991_CR6","volume-title":"Robbins pathologic basis of disease","author":"RS Cotran","year":"1999","unstructured":"Cotran RS, Kumar V, Collins T, Robbins SL. Robbins pathologic basis of disease. Philadelphia: Saunders; 1999."},{"key":"9991_CR7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","volume":"20","author":"ME Hodson","year":"2002","unstructured":"Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20:658\u201364.","journal-title":"Eur Respir J"},{"key":"9991_CR8","first-page":"156S","volume":"94","author":"ME Hodson","year":"1988","unstructured":"Hodson ME. Antibiotic treatment. Aerosol therapy. Chest. 1988;94:156S\u201362.","journal-title":"Chest"},{"key":"9991_CR9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00019053-199712030-00011","volume":"12","author":"KL Goa","year":"1997","unstructured":"Goa KL, Lamb H. Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis. Pharmacoeconomics. 1997;12:409\u201322.","journal-title":"Pharmacoeconomics"},{"key":"9991_CR10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ppul.10348","volume":"36","author":"ME Hodson","year":"2003","unstructured":"Hodson ME, McKenzie S, Harms HK, Koch C, Mastella G, Navarro J, et al. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol. 2003;36:427\u201332.","journal-title":"Pediatr Pulmonol"},{"key":"9991_CR11","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0169-409X(02)00159-X","volume":"54","author":"L Garcia-Contreras","year":"2002","unstructured":"Garcia-Contreras L, Hickey AJ. Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. Adv Drug Deliv Rev. 2002;54:1491\u2013504.","journal-title":"Adv Drug Deliv Rev"},{"key":"9991_CR12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1099\/jmm.0.005728-0","volume":"58","author":"Q Parks","year":"2009","unstructured":"Parks Q, Young R, Poch K, Malcolm K, Vasil M, Nick J. Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J Med Microbiol. 2009;58:492\u2013502.","journal-title":"J Med Microbiol"},{"key":"9991_CR13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1023\/A:1018910200420","volume":"16","author":"R Vanbever","year":"1999","unstructured":"Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res. 1999;16:1735.","journal-title":"Pharm Res"},{"key":"9991_CR14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1023\/A:1018910431216","volume":"11","author":"X Yu","year":"1994","unstructured":"Yu X, Zipp GL, Davidson Iii GWR. The effect of temperature and pH on the solubility of quinolone compounds: estimation of heat of fusion. Pharm Res. 1994;11:522\u20137.","journal-title":"Pharm Res"},{"key":"9991_CR15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1006\/abio.1994.1502","volume":"222","author":"D Sinicropi","year":"1994","unstructured":"Sinicropi D, Baker DL, Prince WS, Shiffer K, Shak S. Colorimetric determination of DNase I activity with a DNA-methyl green substrate. Anal Biochem. 1994;222:351\u20138.","journal-title":"Anal Biochem"},{"key":"9991_CR16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ejpb.2006.03.001","volume":"63","author":"R Lichtinghagen","year":"2006","unstructured":"Lichtinghagen R. Determination of Pulmozyme (dornase alpha) stability using a kinetic colorimetric DNase I activity assay. Eur J Pharm Biopharm. 2006;63:365\u20138.","journal-title":"Eur J Pharm Biopharm"},{"key":"9991_CR17","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard\u2014Eighth edition (M07-A8); 2009."},{"key":"9991_CR18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1099\/jmm.0.45969-0","volume":"54","author":"DD Sriramulu","year":"2005","unstructured":"Sriramulu DD, Lunsdorf H, Lam JS, Romling U. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J Med Microbiol. 2005;54:667\u201376.","journal-title":"J Med Microbiol"},{"key":"9991_CR19","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1002\/jps.21362","volume":"97","author":"J Shur","year":"2008","unstructured":"Shur J, Nevell TG, Ewen RJ, Price R, Smith A, Barbu E, et al. Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy. J Pharm Sci. 2008;97:4857\u201368.","journal-title":"J Pharm Sci"},{"key":"9991_CR20","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1023\/A:1016007818575","volume":"13","author":"HK Chan","year":"1996","unstructured":"Chan HK, AuYeung KL, Gonda I. Effects of additives on heat denaturation of rhDNase in solutions. Pharm Res. 1996;13:756\u201361.","journal-title":"Pharm Res"},{"key":"9991_CR21","doi-asserted-by":"crossref","unstructured":"Cipolla DC, Gonda I, Meserve KC, Weck S, Shire SJ. Formulation and aerosol delivery of recombinant deoxyribonucleac-acid derived human deoxyribonuclease-I. In: Cleland JLLR (ed.) Symposium on Formulation and Delivery of Proteins and Peptides, at the 205th National Meeting of the American-Chemical-Society. Denver, Co; 1993. pp. 322\u201342.","DOI":"10.1021\/bk-1994-0567.ch019"},{"key":"9991_CR22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1208\/s12248-008-9033-8","volume":"10","author":"MD Tsifansky","year":"2008","unstructured":"Tsifansky MD, Yeo Y, Evgenov OV, Bellas E, Benjamin J, Kohane DS. Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J. 2008;10:254\u201360.","journal-title":"AAPS J"},{"key":"9991_CR23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0168-3659(00)00362-X","volume":"70","author":"C Bosquillon","year":"2001","unstructured":"Bosquillon C, Lombry C, Preat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release. 2001;70:329.","journal-title":"J Control Release"},{"key":"9991_CR24","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/jps.1154","volume":"90","author":"C Bosquillon","year":"2001","unstructured":"Bosquillon C, Lombry C, Preat V, Vanbever R. Comparison of particle sizing techniques in the case of inhalation dry powders. J Pharm Sci. 2001;90:2032\u201341.","journal-title":"J Pharm Sci"},{"key":"9991_CR25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2005.09.004","volume":"110","author":"NR Rabbani","year":"2005","unstructured":"Rabbani NR, Seville PC. The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Release. 2005;110:130\u201340.","journal-title":"J Control Release"},{"key":"9991_CR26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jac\/37.4.703","volume":"37","author":"KJ Madaras-Kelly","year":"1996","unstructured":"Madaras-Kelly KJ, Larsson AJ, Rotschafer JC. A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 1996;37:703\u201310.","journal-title":"J Antimicrob Chemother"},{"key":"9991_CR27","doi-asserted-by":"crossref","unstructured":"Ghani M, Soothill JS. Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa. Can J Microbiol. 1997;43.","DOI":"10.1139\/m97-144"},{"key":"9991_CR28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.addr.2008.09.011","volume":"61","author":"N Sanders","year":"2009","unstructured":"Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J. Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev. 2009;61:115\u201327.","journal-title":"Adv Drug Deliv Rev"},{"key":"9991_CR29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/thorax.55.9.795","volume":"55","author":"SR Thomas","year":"2000","unstructured":"Thomas SR, Ray A, Hodson ME, Pitt TL. Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease. Thorax. 2000;55:795\u20137.","journal-title":"Thorax"},{"key":"9991_CR30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1183\/09031936.95.08030381","volume":"8","author":"JM Zahm","year":"1995","unstructured":"Zahm JM, GiroddeBentzmann S, Deneuville E, Perrot-Minnot C, Dabadie A, Pennaforte F, et al. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus. Eur Respir J. 1995;8:381\u20136.","journal-title":"Eur Respir J"},{"key":"9991_CR31","volume-title":"Cystic fibrosis","author":"ME Hodson","year":"2007","unstructured":"Hodson ME, Geddes DM, Bush A. Cystic fibrosis. London: Hodder Arnold; 2007."},{"key":"9991_CR32","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1128\/IAI.73.6.3693-3701.2005","volume":"73","author":"TS Walker","year":"2005","unstructured":"Walker TS, Tomlin KL, Worthen GS, Poch KR, Lieber JG, Saavedra MT, et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun. 2005;73:3693\u2013701.","journal-title":"Infect Immun"},{"key":"9991_CR33","first-page":"333","volume-title":"Cilia, Mucus, and Mucociliary Interactions","author":"R Tomkiewicz","year":"1998","unstructured":"Tomkiewicz R, Kishore C, Freeman J, Rubin B. DNA and actin filament ultrastructure in cystic fibrosis sputum. In: Baum G, Priel Z, Roth Y, Liron N, Ostield E, editors. Cilia, Mucus, and Mucociliary Interactions. New York: Marcel Dekker Inc; 1998. p. 333\u201341."},{"key":"9991_CR34","first-page":"919","volume":"148","author":"CA Sheils","year":"1996","unstructured":"Sheils CA, Kas J, Travassos W, Allen PG, Janmey PA, Wohl ME, et al. Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease. Am J Pathol. 1996;148:919\u201327.","journal-title":"Am J Pathol"},{"key":"9991_CR35","doi-asserted-by":"crossref","first-page":"L1240","DOI":"10.1152\/ajplung.00206.2007","volume":"293","author":"VJ Broughton-Head","year":"2007","unstructured":"Broughton-Head VJ, Shur J, Carroll MP, Smith JR, Shute JK. Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1240\u20139.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"9991_CR36","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.295.5559.1487","volume":"295","author":"CB Whitchurch","year":"2002","unstructured":"Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science. 2002;295:1487.","journal-title":"Science"},{"key":"9991_CR37","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1128\/AAC.31.10.1502","volume":"31","author":"BL Prosser","year":"1987","unstructured":"Prosser BL, Taylor D, Dix BA, Cleeland R. Method of evaluating effects of antibiotics on bacterial biofilm. Antimicrob Agents Chemother. 1987;31:1502\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"9991_CR38","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.mi.41.100187.002251","volume":"41","author":"JW Costerton","year":"1987","unstructured":"Costerton JW, Cheng KJ, Geesey GG, Ladd TI, Nickel JC, Dasgupta M, et al. Bacterial biofilms in nature and disease. Annu Rev Microbiol. 1987;41:435\u201364.","journal-title":"Annu Rev Microbiol"},{"key":"9991_CR39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2710.1995.tb00703.x","volume":"20","author":"RD Bates","year":"1995","unstructured":"Bates RD, Nahata MC. Aerosolized dornase alpha (rhDNase) in cystic fibrosis. J Clin Pharm Ther. 1995;20:313\u20135.","journal-title":"J Clin Pharm Ther"},{"key":"9991_CR40","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/01.mcp.0000245712.51514.a1","volume":"12","author":"F Ratjen","year":"2006","unstructured":"Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med. 2006;12:428\u201332.","journal-title":"Curr Opin Pulm Med"},{"key":"9991_CR41","doi-asserted-by":"crossref","first-page":"e714","DOI":"10.1542\/peds.111.6.e714","volume":"111","author":"MM Chalumeau","year":"2003","unstructured":"Chalumeau MM, Tonnelier SS, D\u2019Athis PP, Trluyer JJ-M, Gendrel DD, Brart GG, et al. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics. 2003;111:e714\u20139.","journal-title":"Pediatrics"},{"key":"9991_CR42","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1378\/chest.06-1524","volume":"131","author":"CKK Lee","year":"2007","unstructured":"Lee CKK, Boyle MP, Diener-West M, Brass-Ernst L, Noschese M, Zeitlin PL. Levofloxacin pharmacokinetics in adult cystic fibrosis. Chest. 2007;131:796\u2013802.","journal-title":"Chest"},{"key":"9991_CR43","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4187\/aarc0537","volume":"54","author":"DEDE Geller","year":"2009","unstructured":"Geller DEDE. Aerosol antibiotics in cystic fibrosis. Respir Care. 2009;54:658\u201370.","journal-title":"Respir Care"},{"key":"9991_CR44","doi-asserted-by":"crossref","unstructured":"Pearson J. Inhalation Technologies\u2014A Breath of Fresh Air. Drug Delivery Report. 2006;19\u201321. Spring\/Summer).","DOI":"10.3833\/pdr.v2006i73.488"},{"key":"9991_CR45","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijpharm.2005.09.010","volume":"305","author":"LG Sweeney","year":"2005","unstructured":"Sweeney LG, Wang Z, Loebenberg R, Wong JP, Lange CF, Finlay WH. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm. 2005;305:180\u20135.","journal-title":"Int J Pharm"},{"key":"9991_CR46","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jconrel.2004.07.022","volume":"99","author":"C Bosquillon","year":"2004","unstructured":"Bosquillon C, Rouxhet PG, Ahimou F, Simon D, Culot C, Preat V, et al. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J Control Release. 2004;99:357\u201367.","journal-title":"J Control Release"},{"key":"9991_CR47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1023\/A:1018879331061","volume":"16","author":"A Ben-Jebria","year":"1999","unstructured":"Ben-Jebria A, Chen D, Eskew ML, Vanbever R, Langer R, Edwards DA. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res. 1999;16:555\u201361.","journal-title":"Pharm Res"},{"key":"9991_CR48","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/jps.10346","volume":"92","author":"V Codrons","year":"2003","unstructured":"Codrons V, Vanderbist F, Verbeeck RK, Arras M, Lison D, Pr\u00e9at V, et al. Systemic delivery of parathyroid hormone (1\u201334) using inhalation dry powders in rats. J Pharm Sci. 2003;92:938\u201350.","journal-title":"J Pharm Sci"},{"key":"9991_CR49","unstructured":"The United States Pharmacopeia: The National Formulary (USP32\/NF27), The United States Pharmacopeial Convention, 2009."},{"key":"9991_CR50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jconrel.2004.01.027","volume":"96","author":"C Bosquillon","year":"2004","unstructured":"Bosquillon C, Pr\u00e9at V, Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J Control Release. 2004;96:233\u201344.","journal-title":"J Control Release"},{"key":"9991_CR51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/089426802760292636","volume":"15","author":"T Weuthen","year":"2002","unstructured":"Weuthen T, Roeder S, Brand P, Mllinger B, Scheuch G. In vitro testing of two formoterol dry powder inhalers at different flow rates. J Aerosol Med. 2002;15:297\u2013303.","journal-title":"J Aerosol Med"},{"key":"9991_CR52","doi-asserted-by":"crossref","first-page":"12001","DOI":"10.1073\/pnas.182233999","volume":"99","author":"N Tsapis","year":"2002","unstructured":"Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. PNAS. 2002;99:12001\u20135.","journal-title":"PNAS"},{"key":"9991_CR53","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s11095-007-9475-1","volume":"25","author":"R Vehring","year":"2008","unstructured":"Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25:999\u20131022.","journal-title":"Pharm Res"},{"key":"9991_CR54","doi-asserted-by":"crossref","unstructured":"Sung JC, Padilla DJ, Garcia-Contreras L, Verberkmoes JL, Durbin D, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DA. Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery. Pharm Res. 2009.","DOI":"10.1007\/s11095-009-9894-2"},{"key":"9991_CR55","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tibtech.2007.09.005","volume":"25","author":"JC Sung","year":"2007","unstructured":"Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25:563\u201370.","journal-title":"Trends Biotechnol"},{"key":"9991_CR56","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/03602550600685275","volume":"24","author":"M Ameri","year":"2006","unstructured":"Ameri M, Maa Y-F. Spray drying of biopharmaceuticals: stability and process considerations. Drying Technol. 2006;24:763\u20138.","journal-title":"Drying Technol"},{"key":"9991_CR57","doi-asserted-by":"crossref","first-page":"9188","DOI":"10.1073\/pnas.87.23.9188","volume":"87","author":"S Shak","year":"1990","unstructured":"Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA. 1990;87:9188\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9991_CR58","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1128\/jb.184.4.1140-1154.2002","volume":"184","author":"K Sauer","year":"2002","unstructured":"Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol. 2002;184:1140\u201354.","journal-title":"J Bacteriol"},{"key":"9991_CR59","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/jac\/24.5.647","volume":"24","author":"H Anwar","year":"1989","unstructured":"Anwar H, Dasgupta M, Lam K, Costerton JW. Tobramycin resistance of mucoid Pseudomonas aeruginosa biofilm grown under iron limitation. J Antimicrob Chemother. 1989;24:647\u201355.","journal-title":"J Antimicrob Chemother"},{"key":"9991_CR60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1286-4579(00)01349-6","volume":"3","author":"N H\u00f8iby","year":"2001","unstructured":"H\u00f8iby N, Johansen HK, Moser C, Song Z, Ciofu O, Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 2001;3:23\u201335.","journal-title":"Microbes Infect"},{"key":"9991_CR61","doi-asserted-by":"crossref","unstructured":"Tsifansky MD, Yeo Y, Evgenov OV, Bellas E, Benjamin J, Kohane DS. Microparticles for Inhalational Delivery of Antipseudomonal Antibiotics. AAPS J. 2008.","DOI":"10.1208\/s12248-008-9033-8"},{"key":"9991_CR62","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijantimicag.2008.07.012","volume":"33","author":"M Tr\u00e9-Hardy","year":"2009","unstructured":"Tr\u00e9-Hardy M, Mac\u00e9 C, Manssouri NE, Vanderbist F, Traore H, Devleeschouwer MJ. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model. Int J Antimicrob Agents. 2009;33:40\u20135.","journal-title":"Int J Antimicrob Agents"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-009-9991-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-009-9991-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-009-9991-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T01:43:16Z","timestamp":1559353396000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-009-9991-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,22]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["9991"],"URL":"https:\/\/doi.org\/10.1007\/s11095-009-9991-2","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,22]]}}}